- Supernus Pharmaceuticals (SUPN) shares spike 24%, adding to an 8% gain in regular trading, after the company announces the FDA has approved Orenitram extended-release tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.
- The news broke last week, but it appears that investors have had in their memory that Supernus has a development/licensing agreement for the drug with United Therapeutics jolted by the PR.
- Supernus developed the formulation under an agreement with United Therapeutics (UTHR +30.4%), whose shares rocketed when the approval was announced earlier today. United will pay Supernus certain milestone fees and royalties on global product sales.
Supernus spikes 24% AH on Orenitram PR
Dec 23 2013, 17:35 ET